News

The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at Gladstone Institutes to develop a CRISPR-based therapy for CMT2A. This CMTA Strategy To Accelerate Research (CMTA-STAR) initiative aims to create a single solution for multiple ...

CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member and clinic director of the CMTA Center of Excellence at the C. Besta Neurological Institute in Milan, Italy, Davide Pareyson, MD, and colleagues review the latest advancements in Charcot-Marie-Tooth disease (CMT). ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Joshua A. Smith, DO, as a CMTA Center of Excellence at the University of Pittsburgh Medical Center (UPMC) in ...

The Charcot-Marie-Tooth Association (CMTA) announces a $90,860 investment in a new imaging research project at UC San Diego to study how MFN2 mutations drive CMT2A progression. This CMTA Strategy To Accelerate Research (CMTA-STAR) project will equip scientists with tools to ...

Join us as we talk with Dr. Katherine Forsey, CMTA’s Chief Research Officer. Dr. Forsey shares her journey living with CMT, the impact of CMTA’s Strategy To Accelerate Research (CMTA-STAR), CMTA’s Patients as Partners in Research platform, CMTA’s Patient & ...